Trimethylamine N-oxide as a key microbial mediator in the progression of diabetic kidney disease

Table 1 Microbial-metabolic disturbances that promote trimethylamine N-oxide -driven pathways in diabetic kidney disease[4-8]

Pathway	Microbial derangement	Physiological consequence	Relevance to TMAO biology
Outer-membrane-vesicle-associated LPS production	Increase in gram-negative organisms	Activation of TLR4, NF-κB, and NLRP3 pathways	Enhances renal responsiveness to TGF-β-mediated fibrotic signalling
Depletion of short-chain-fatty-acid-producing taxa	Reduction in Faecalibacterium prausnitzii and Lachnospira	Loss of GPR43 and GPR109A anti-inflammatory signalling	Diminishes intrinsic anti-fibrotic buffering and lowers resistance to TMAO-driven injury
Enhanced microbial trimethylamine formation	Expansion of TMA-generating microbial communities	Increased luminal TMA availability	Greater hepatic conversion of TMA to TMAO, elevating systemic TMAO burden
Impaired intestinal barrier integrity	Reduced expression of ZO-1 and occludin	Increased translocation of microbial products into systemic circulation	Augments systemic inflammatory activation and magnifies TMAO-associated renal effects

LPS: Lipopolysaccharide; TLR4: Toll-like receptor 4; NF-κB: Nuclear factor-κB; NLRP3: NOD-like receptor family pyrin domain containing 3; TMA: Trimethylamine; TMAO: Trimethylamine-N-oxide; ZO-1: Zonula occludens-1.

Table 2 Global diabetes trends that intensify trimethylamine N-oxide -associated fibrotic pathways[2,11-13]

Epidemiologic trend	Underlying biological mechanism	Implication for the TMAO pathway
Increasing consumption of processed foods	Higher dietary intake of choline and carnitine	Greater availability of substrates for microbial trimethylamine formation
Rapid urbanisation	Westernisation of gut microbial composition	Expansion of microbial taxa capable of producing TMA
High proportion of undiagnosed diabetes	Delayed identification of renal injury and prolonged metabolic stress	Increased susceptibility of the kidney to TMAO-mediated fibrotic responses
Rising diabetes prevalence in low- and middle-income regions	Nutritional transition with reduced fibre intake and altered microbial ecology	Amplification of dysbiosis favouring TMA-generating microbiota
Increasing premature mortality in diabetes	Heightened oxidative and inflammatory burden	Lowered threshold for TMAO-driven ROS generation and Smad activation

TMA: Trimethylamine; TMAO: Trimethylamine-N-oxide; ROS: Reactive oxygen species.

Table 3 Mechanistic and therapeutic insights derived from microbial trimethylamine inhibition[10,14,15]

DMB observation	Mechanistic insight	Relevance to diabetic kidney disease
Inhibition of CutC/D TMA lyases	Proximal blockade of microbial TMA formation	Lowers the upstream substrate load driving TMAO accumulation
Demonstrated activity in human fecal cultures	Effective within complex microbial ecosystems	Applicable even in dysbiotic communities characteristic of diabetes
No observed hepatic, renal, or metabolic toxicity	Preserves physiological homeostasis	Suitable for long-term use in chronic disease settings
Reduction of TMA-producing taxa	Favourable restructuring of gut microbial composition	Addresses dysbiosis that contributes to DN severity
Prevention of fibrotic signalling	Decreases NOX4, pro-inflammatory cytokines, and Smad activation	Slows the trajectory of diabetic kidney injury

DMB: 3,3-dimethyl-1-butanol; CutC/D: Choline trimethylamine lyase enzyme complex; TMA: Trimethylamine; TMAO: Trimethylamine-N-oxide; NOX4: NADPH oxidase-4; DN: Diabetic nephropathy; DKD: Diabetic kidney disease.

Table 4 Central experimental insights defining the fibrotic role of trimethylamine-N-oxide[1,9,10,15,17]

Experimental component	Key observation	Interpretation
Microbial profiling	Increase in TMA-producing taxa in diabetic animals	Dysbiosis acts as the initiating metabolic trigger
Plasma TMAO levels	Progressive rise during disease evolution	Represents an early and persistent metabolic signature
Microbiota transplantation	Non-diabetic recipients develop renal injury and fibrosis	Demonstrates microbiota-mediated transmission of pathogenic signals
Fibrotic markers	Upregulation of TGF-β1, Smad2/3, and α-SMA	Indicates direct activation of canonical profibrotic pathways
Inhibition of TMA formation	Reversal of structural and biochemical injury	Confirms causal and therapeutically reversible role of the TMAO-driven fibrotic pathway

TMAO: Trimethylamine-N-oxide; α-SMA: Alpha-smooth muscle actin; TGF-β: Transforming growth factor-beta.